John J. Ryan
( out of 289 reviews )

John J. Ryan, MD, MB, BCh, BAO

Languages spoken: English

Clinical Locations

University of Utah Hospital

Salt Lake City
801-585-7676

Cardiovascular Center

Cardiovascular Center
Salt Lake City
801-585-7676

  • Dr. Ryan is a highly esteemed specialist in Cardiovascular Medicine and Pulmonary Hypertension, recognized internationally for his expertise. He is a Professor of Medicine in the Division of Cardiovascular Medicine at the University of Utah. In addition, Dr. Ryan serves as the cardiology fellowship director and the director of the pulmonary hypertension program.

    Dr. Ryan's contributions extend beyond academia, as he also acts as a Sports Cardiology Consultant for prestigious organizations such as the United States Olympic Committee, the International Olympic Committee, the National Basketball Association, Major League Soccer, and the NCAA.

    His involvement in the field is further demonstrated by his active participation on the editorial boards of Circulation, Circulation: Cardiovascular Quality and Outcomes, Circulation: Heart Failure, The Canadian Journal of Cardiology, among others. Dr. Ryan has also made significant contributions as an author on the guidelines from the CHEST on the treatment of pulmonary hypertension.

    Throughout his career, Dr. Ryan has published over 150 research publications, showcasing his work in leading medical journals such as The New England Journal of Medicine, Nature Medicine, The British Medical Journal, Circulation, CHEST, and The Journal of the American College of Cardiology.

    Dr. Ryan's remarkable accomplishments and dedication to advancing cardiovascular medicine make him an invaluable asset to the field.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Advanced Heart Failure & Transplant Cardiology)
    American Board of Internal Medicine (Sub: Cardiovascular Disease)
    Certification Board of Nuclear Cardiology
    National Board of Echocardiography (Special Competence in Adult Echocardiography)
    National Board of Physicians and Surgeons
    Royal College of Physicians in Ireland

    Patient Rating

    4.9 /5
    ( out of 289 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    January 24, 2025
    UNIVERSITY HOSPITAL

    Considering his exceptional credentials Dr. Ryan is a really down to earth guy who listens and communicates well. I trust him with all my heart:).

    January 09, 2025
    UNIVERSITY HOSPITAL

    Very professional yet compassionate and understanding

    December 22, 2024
    UH HOSPITALS AND CLINICS

    He is patient focused, and talks with you, not at you.

    December 15, 2024
    UH HOSPITALS AND CLINICS

    Very happy

    December 13, 2024
    UH HOSPITALS AND CLINICS

    Dr. John Ryan is a skilled and caring physician. I am confident in the care that he provides. He answers all the questions that I present and in a way that I understand. His counsel is trusted.

    December 12, 2024
    UH HOSPITALS AND CLINICS

    Dr. Ryan treats patients with respect and courtesy! He listens, and explains things carefully so the patient can clearly understand! I would highly recommend Dr Ryan!

    December 06, 2024
    UH HOSPITALS AND CLINICS

    An XCLNT (Excellent) Service (O_O) Highly Recommended Doctor (*_*) Doctor John. J. Ryan is a Professional, Knowledgeable, Caring and Friendly Human Being (o)__(o) and also His Team

    November 23, 2024
    UNIVERSITY HOSPITAL

    DR. Ryan has always made sure all my health issues were addressed and taken care of and has always explained everything to me in a way I could understand.

    November 21, 2024
    UNIVERSITY HOSPITAL

    Dr Ryan is knowledgeable, thoughtful and caring.

    See More Patient Comments

  • Dr. Ryan is a highly esteemed specialist in Cardiovascular Medicine and Pulmonary Hypertension, recognized internationally for his expertise. He is a Professor of Medicine in the Division of Cardiovascular Medicine at the University of Utah. In addition, Dr. Ryan serves as the cardiology fellowship director and the director of the pulmonary hypertension program.

    Dr. Ryan's contributions extend beyond academia, as he also acts as a Sports Cardiology Consultant for prestigious organizations such as the United States Olympic Committee, the International Olympic Committee, the National Basketball Association, Major League Soccer, and the NCAA.

    His involvement in the field is further demonstrated by his active participation on the editorial boards of Circulation, Circulation: Cardiovascular Quality and Outcomes, Circulation: Heart Failure, The Canadian Journal of Cardiology, among others. Dr. Ryan has also made significant contributions as an author on the guidelines from the CHEST on the treatment of pulmonary hypertension.

    Throughout his career, Dr. Ryan has published over 150 research publications, showcasing his work in leading medical journals such as The New England Journal of Medicine, Nature Medicine, The British Medical Journal, Circulation, CHEST, and The Journal of the American College of Cardiology.

    Dr. Ryan's remarkable accomplishments and dedication to advancing cardiovascular medicine make him an invaluable asset to the field.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor (Clinical)
    Academic Divisions Cardiovascular Medicine
    Board Certification
    American Board of Internal Medicine (Sub: Advanced Heart Failure & Transplant Cardiology)
    American Board of Internal Medicine (Sub: Cardiovascular Disease)
    Certification Board of Nuclear Cardiology
    National Board of Echocardiography (Special Competence in Adult Echocardiography)
    National Board of Physicians and Surgeons
    Royal College of Physicians in Ireland

    Education history

    Research Fellow Advanced Cardiovascular - University of Chicago Medical Center Research Fellow
    Fellowship Cardiology - University of Chicago Chief Fellow
    Fellowship Cardiovascular - University of Chicago Medical Center Fellow
    Chief Resident Internal Medicine - Boston Medical Center Chief Medical Resident
    Residency Internal Medicine - Boston Medical Center Resident
    Internship Internal Medicine and General Surgery - Cork University Hospital Intern
    Professional Medical Medicine - University College Cork, Ireland M.D.

    Selected Publications

    Journal Article

    1. Iacovelli JJ, Alpenglow JK, Ratchford SM, Craig JC, Simmons JM, Zhao J, Reese V, Bunsawat K, Ma CL, Ryan JJ, Wray DW (2024). Statin therapy improves locomotor muscle microvascular reactivity in patients with heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol, 327(4), H859-H865. (Read full article)
    2. Kogelschatz B, Penn BA, Leavitt AJ, Dranow E, Ma CL, Ryan JJ (2024). Efficacy of Activity Trackers in Patients With Heart Failure With Preserved Ejection Fraction. Cureus, 16(7), e65117. (Read full article)
    3. Alpenglow JK, Bunsawat K, Francisco MA, Broxterman RM, Craig JC, Iacovelli JJ, Weavil JC, Harrison JD, Morgan DE, Silverton NA, Reese VR, Ma CL, Ryan JJ, Wray DW (2024). α-Adrenergic regulation of skeletal muscle blood flow during exercise in patients with heart failure with preserved ejection fraction. J Physiol, 602(14), 3401-3422. (Read full article)
    4. Alpenglow JK, Bunsawat K, Francisco MA, Craig JC, Iacovelli JJ, Ryan JJ, Wray DW (2023). Evidence of impaired functional sympatholysis in patients with heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol, 325(4), H806-H813. (Read full article)
    5. Alamri AK, Ma CL, Ryan JJ (2023). Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going? Drugs, 83(7), 577-585. (Read full article)
    6. Ratchford SM, Bunsawat K, Alpenglow JK, Zhao J, Wright JB, Ryan JJ, Wray DW (2022). Improved vascular function and functional capacity following l-citrulline administration in patients with heart failure with preserved ejection fraction: a single-arm, open-label, prospective pilot study. J Appl Physiol (1985), 134(2), 328-338. (Read full article)
    7. Ingram D, Alamri AK, Penn BA, Mayeux JD, Ma CL, Clapham KR, Abraham AE, Klanderud D, Sadeh B, Beck EM, Hatton ND, Ryan JJ (2022). Characteristics of Patients With Pulmonary Arterial Hypertension in a Pulmonary Hypertension Association-Accredited Comprehensive Care Center: A Contrast in Features When Compared With US National Registry Data. Cureus, 14(11), e31764. (Read full article)
    8. Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, De Marco T, Frantz RP, Hemnes A, Mathai SC, Rosenzweig EB, Ryan JJ, Thenappan T, PHAR Investigators (2022). Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc, 11, e024969. (Read full article)
    9. Ratchford SM, Lee JF, Bunsawat K, Alpenglow JK, Zhao J, Ma CL, Ryan JJ, Khor LL, Wray DW (2022). The Impact of Obesity on the Regulation of Muscle Blood Flow during Exercise in Patients with Heart Failure with a Preserved Ejection Fraction. J Appl Physiol (1985), 132(5), 1240-1249. (Read full article)
    10. Minhas J, Narasimmal SP, M Bull T, Marco T, McConnell JW, Lammi MR, Thenappan T, P Feldman J, S Sager J, B Badesch D, Ryan JJ, C Grinnan D, Zwicke D, M Horn E, Elwing JM, Moss JE, Eggert M, Shlobin OA, P Frantz R, D Bartolome S, Mathai SC, Mazimba S, C Pugliese S, Al-Naamani N (2021). Health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR). Pulm Circ, 11(4), 20458940211053196. (Read full article)
    11. Vahdatpour CA, Ryan JJ, Zimmerman JM, MacCormick SJ, Palevsky HI, Alnuaimat H, Ataya A (2021). Advanced airway management and respiratory care in decompensated pulmonary hypertension. Heart Fail Rev. (Read full article)
    12. DuBrock HM, Burger CD, Bartolome SD, Feldman JP, Ivy DD, Rosenzweig EB, Sager JS, Presberg KW, Mathai SC, Lammi MR, Klinger JR, Eggert M, De Marco T, Elwing JM, Badesch D, Bull TM, Cadaret LM, Ramani G, Thenappan T, Ford HJ, Al-Naamani N, Simon MA, Mazimba S, Runo JR, Chakinala M, Horn EM, Ryan JJ, Frantz RP, Krowka MJ (2021). Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. Pulm Circ, 11(3), 20458940211020913. (Read full article)
    13. Mayeux JD, Pan IZ, Dechand J, Jacobs JA, Jones TL, McKellar SH, Beck E, Hatton ND, Ryan JJ (2020). Management of Pulmonary Arterial Hypertension. Curr Cardiovasc Risk Rep, 15(1), 2. (Read full article)
    14. Lee JD, Burger CD, Delossantos GB, Grinnan D, Ralph DD, Rayner SG, Ryan JJ, Safdar Z, Ventetuolo CE, Zamanian RT, Leary PJ (2020). A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. Ann Am Thorac Soc, 17(12), 1576-1582. (Read full article)
    15. Ratchford SM, Clifton HL, La Salle DT, Broxterman RM, Lee JF, Ryan JJ, Hopkins PN, Wright JB, Trinity JD, Richardson RS, Wray DW (2020). Cardiovascular responses to rhythmic handgrip exercise in heart failure with preserved ejection fraction. J Appl Physiol (1985), 129(6), 1267-1276. (Read full article)
    16. Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, Maloney J, De Marco T, Ivy D, Thenappan T, Sager JS, Ryan JJ, Mazimba S, Hirsch R, Chakinala M, Shlobin O, Lammi M, Zwicke D, Robinson J, Benza RL, Klinger J, Grinnan D, Mathai S, Badesch D (2020). Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. Pulm Circ, 10(4), 2045894020964342. (Read full article)
    17. Zenger B, Swink JM, Turner JL, Bunch TJ, Ryan JJ, Shah RU, Turakhia MP, Piccini JP, Steinberg BA (2020). Social Media Influence Does Not Reflect Scholarly or Clinical Activity in Real Life. Circ Arrhythm Electrophysiol, 13(11), e008847. (Read full article)
    18. Wohlfahrt P, Stehlik J, Pan IZ, Ryan JJ (2020). Empowering People Living with Heart Failure. Heart Fail Clin, 16(4), 409-420. (Read full article)
    19. Ryan JJ, Melendres-Groves L, Zamanian RT, Oudiz RJ, Chakinala M, Rosenzweig EB, Gomberg-Maitland M (2020). Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. Pulm Circ, 10(2), 2045894020920153. (Read full article)
    20. Leary PJ, Jenny NS, Bluemke DA, Kawut SM, Kronmal RA, Lima JA, Maron BA, Ralph DD, Rayner SG, Ryan JJ, Steinberg ZL, Hinckley Stukovsky KD, Tedford RJ (2019). Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study. J Heart Lung Transplant, 39(1), 45-52. (Read full article)
    21. Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, OMeara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD, PARAGON-HF Investigators (2019). Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol, 74(23), 2858-2873. (Read full article)
    22. Ratchford SM, Clifton HL, Gifford JR, LaSalle DT, Thurston TS, Bunsawat K, Alpenglow JK, Richardson RS, Wright JB, Ryan JJ, Wray DW (2019). Impact of acute antioxidant administration on inflammation and vascular function in heart failure with preserved ejection fraction. Am J Physiol Regul Integr Comp Physiol, 317(5), R607-R614. (Read full article)
    23. Maron BA, Ryan JJ (2019). A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine. Circulation, 139(16), 1861-1864. (Read full article)
    24. Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB (2019). Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest, 155(3), 565-586. (Read full article)
    25. Franco V, Ryan JJ, McLaughlin VV (2018). Pulmonary Hypertension in Women. Heart Fail Clin, 15(1), 137-145. (Read full article)
    26. Cirulis MM, Ryan JJ, Archer SL (2019). Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Pulm Circ, 9(1), 2045894019834890. (Read full article)
    27. Cirulis MM, Huston JH, Sardar P, Suksaranjit P, Wilson BD, Hatton ND, Liou TG, Ryan JJ (2018). Right-to-left ventricular end diastolic diameter ratio in severe sepsis and septic shock. J Crit Care, 48, 307-310. (Read full article)
    28. Agarwal S, Spiekerkoetter E, Austin ED, de Jesus Perez V, Dezfulian C, Maron BA, Ryan JJ, Starks MA, Yu PB, Bonnet S, Perman SM (2018). Career Development of Young Physician-Scientists in the Cardiovascular Sciences: Perspective and Advice From the Early Career Committee of the Cardiopulmonary, Critical Care, and Resuscitation Council of the American Heart Association. Circ Res, 122(10), 1330-1333. (Read full article)
    29. Ryan JJ, Waxman AB (2018). The Dyspnea Clinic. Circulation, 137(19), 1994-1996. (Read full article)
    30. Thenappan T, Ormiston ML, Ryan JJ, Archer SL (2018). Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ, 360, j5492. (Read full article)
    31. Keefe AC, Hymas JC, Emerson LL, Ryan JJ (2017). An atypical presentation of cardiac tamponade and periorbital swelling in a patient with eosinophilic granulomatosis with polyangiitis: a case report. J Med Case Rep, 11(1), 271. (Read full article)
    32. Cruz L, Ryan JJ (2017). Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci, 2(3), 341-343. (Read full article)
    33. Ryan JJ (2016). Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease. JACC Basic Transl Sci, 1(7), 684-686. (Read full article)
    34. Ryan JJ (2016). CD47-Blocking Antibodies and Atherosclerosis. JACC Basic Transl Sci, 1(5), 413-415. (Read full article)
    35. Ryan JJ, Suksaranjit P, Hatton N, Bull DA, Wilson BD (2015). Eisenmenger syndrome with unrepaired patent ductus arteriosus. Circulation, 131(16), e409-11. (Read full article)
    36. Harrison A, Hatton N, Ryan JJ (03/11/2015). The right ventricule under pressure: evaluating the adaptive and maladaptive changes in the right ventricle in pulmonary arterial hypertension using echocardiography. Pulm Circ, 5(1), 29-47.
    37. Ryan JJ, Butrous G, Maron BA (2014). The Heterogeneity of Clinical Practice Patterns among an International Cohort of Pulmonary Arterial Hypertension Experts. Pulm Circ.
    38. Ryan JJ, Archer SL (2014). The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res, 115(1), 176-88. (Read full article)
    39. Tong C, Ahmad T, Brittain EL, Bunch TJ, Damp JB, Dardas T, Hijar A, Hill JA, Hilliard AA, Houser SR, Jahangir E, Kates AM, Kim D, Lindman BR, Ryan JJ, Rzeszut AK, Sivaram CA, Valente AM, Freeman AM (2014). Challenges Facing Early Career Academic Cardiologists. J Am Coll Cardiol.
    40. Harrison A, Wilson BD, Ryan JJ (2014). Exploring the Role of Aldosterone in Right Ventricular Function. Can J Cardiol, 30(2), 155-158.
    41. Piao L, Fang YH, Parikh K, Ryan JJ, Toth PT, Archer SL (2013). Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med (Berl), 91(10), 1185-97. (Read full article)
    42. Ryan JJ (2013). Chloroquine in pulmonary arterial hypertension: a new role for an old drug? Circ Cardiovasc Genet, 6(3), 310-1. (Read full article)
    43. Ryan JJ, Marsboom G, Fang YH, Toth PT, Morrow E, Luo N, Piao L, Hong Z, Ericson K, Zhang HJ, Han M, Haney CR, Chen CT, Sharp WW, Archer SL (2013). PGC1alpha-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension. Am J Respir Crit Care Med, 187(8), 865-78. (Read full article)
    44. Kim GH, Ryan JJ, Archer SL (03/01/2013). Epigenetics in Cardiovascular Medicine (ahead of print). Antioxid Redox Signal.
    45. Piao L, Sidhu VK, Fang YH, Ryan JJ, Parikh KS, Hong Z, Toth PT, Morrow E, Kutty S, Lopaschuk GD, Archer SL (2013). FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med (Berl), 91(3), 333-46. (Read full article)
    46. Hong Z, Kutty S, Toth PT, Marsboom G, Hammel JM, Chamberlain C, Ryan JJ, Zhang HJ, Sharp WW, Morrow E, Trivedi K, Weir EK, Archer SL (03/1/2013). Role of dynamin-related protein 1 (drp1)-mediated mitochondrial fission in oxygen sensing and constriction of the ductus arteriosus. Circ Res, 112(5), 802-15.
    47. Ryan JJ, Marsboom G, Fang YH, Toth PT, Morrow E, Luo N, Piao L, Hong Z, Zhang HJ, Haney C, Chen CT, Sharp W, Archer SL (02/28/2013). Mitofusion-2 deficiency promotes smooth muscle cell proliferation and mitofusin-2 gene therapy regresses experimental pulmonary arterial hypertension in females. Am J Respir Crit Care Med.
    48. Ryan JJ, Musunuru K, Prakash SK (2013). Top advances in functional genomics and translational biology for 2012. Circ Cardiovasc Genet, 6(1), 132-4. (Read full article)
    49. Ryan JJ, Marsboom G, Archer SL (2013). Rodent models of group 1 pulmonary hypertension. Handb Exp Pharmacol, 218, 105-49. (Read full article)
    50. Archer SL, Fang YH, Ryan JJ, Piao L (2013). Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ, 3(1), 144-52. (Read full article)
    51. Piao L, Fang YH, Parikh KS, Ryan JJ, DSouza KM, Theccanat T, Toth PT, Pogoriler J, Paul J, Blaxall BC, Akhter SA, Archer SL (12/01/2012). GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation, 126(24), 2859-69.
    52. Marsboom G, Toth PT, Ryan JJ, Hong Z, Wu X, Fang YH, Thenappan T, Piao L, Zhang HJ, Pogoriler J, Chen Y, Morrow E, Weir EK, Rehman J, Archer SL (2012). Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res, 110(11), 1484-97. (Read full article)
    53. Ryan JJ, Mehta R, Thiruvoipati T, Ward RP, Williams KA (2012). Stress-only imaging in patients with prior SPECT MPI: a simulation study. J Nucl Cardiol, 19(2), 311-8. (Read full article)
    54. Ryan JJ, Rich JD, Thiruvoipati T, Swamy R, Kim GH, Rich S (2012). Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J, 163(4), 589-94. (Read full article)
    55. Marsboom G, Wietholt C, Haney CR, Toth PT, Ryan JJ, Morrow E, Thenappan T, Bache-Wiig P, Piao L, Paul J, Chen CT, Archer SL (2012). Lung (1)(8)F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med, 185(6), 670-9. (Read full article)
    56. Ryan JJ, Thenappan T, Luo N, Ha T, Patel AR, Rich S, Archer SL (2012). The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulm Circ, 2(1), 107-21. (Read full article)
    57. Kim GH, Ryan JJ, Marsboom G, Archer SL (2011). Epigenetic mechanisms of pulmonary hypertension. Pulm Circ, 1(3), 347-56. (Read full article)
    58. Maree AO, Vangjeli C, Jneid H, Ryan J, Cox D, Cannon CP, Shields DC, Fitzgerald DJ (2010). G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial. J Thromb Haemost, 8(5), 934-41. (Read full article)
    59. Shin JH, Pokharna HK, Williams KA, Mehta R, Ward RP (2009). SPECT myocardial perfusion imaging with prone-only acquisitions: correlation with coronary angiography. J Nucl Cardiol, 16(4), 590-6. (Read full article)
    60. Ryan AM, Ryan J, Wan-Ahmed M, Hardiman O, Farrell MA, McNamara B, Sweeney BJ (2009). Vacuolar leucoencephalopathy and pulvinar sign in association with coeliac disease.LID - 10.1136/bcr.08.2008.0650 [doi]LID - bcr08.2008.0650 [pii]. BMJ Case Rep, 2009. (Read full article)
    61. Ryan JJ, Ryan A, McGrath E (2004). Is Secondary Care Paediatrics Evidenced Based? An Evaluation in a County Hospital. 2/3, 3.

    Review

    1. Tsarova K, Morgan AE, Melendres-Groves L, Ibrahim MM, Ma CL, Pan IZ, Hatton ND, Beck EM, Ferrel MN, Selzman CH, Ingram D, Alamri AK, Ratcliffe MB, Wilson BD, Ryan JJ (2022). Imaging in Pulmonary Vascular Disease-Understanding Right Ventricle-Pulmonary Artery Coupling. [Review]. Compr Physiol, 12(4), 3705-3730. (Read full article)
    2. Jacobs JA, Jahangir E, Ryan JJ (2022). Differentiating pulmonary hypertension associated with protein kinase inhibitors. [Review]. Pulm Circ, 12(2), e12075. (Read full article)
    3. Alamri AK, Ma CL, Ryan JJ (2021). Left Heart Disease-Related Pulmonary Hypertension. [Review]. Cardiol Clin, 40(1), 69-76. (Read full article)
    4. Ryan J, Bloch K, Archer SL (2011). Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH. [Review]. Int J Clin Pract Suppl, (172), 15-34. (Read full article)
    5. Steiling K, Ryan J, Brody JS, Spira A (2008). The field of tissue injury in the lung and airway. [Review]. Cancer Prev Res (Phila), 1(6), 396-403. (Read full article)

    Book Chapter

    1. Ryan JJ, Marsboom G, Archer S (2013). Pulmonary Hypertension: Animal Models. In Humbert M, Evgenov OV, Stasch JP (Eds.), Pharmacotherapy of Pulmonary Hypertension (Chapter 5).
    2. Archer SL, Ryan JJ, Rich S, Nathan S, Tsai K, Patel AR, Fang Yh, Piao L (2012). The Right Ventricle: Reemergence of the Forgotten Ventricle. In Joseph A. Hill and Eric N. Olson (Eds.), Muscle: Fundamental Biology and Mechanisms of Disease (CHAPTER 38).
    3. Archer SL, Ryan J (2011). Mitochondrial ROS and Redox State in Pulmonary Vascular O2 sensing. In Yuan JXJ, Garcia JGN , Hales CA, Stuart R, Archer SL, West JB (Eds.), Textbook of Pulmonary Vascular Disease (CHAPTER 19).
    4. Gomberg-Maitland M, Thenappan T, Ryan J, Cipriani N, Hussain A, Fedson S, Archer SL (2011). Cor Pulmonale. In Yuan JXJ, Garcia JGN , Hales CA, Stuart R, Archer SL, West JB (Eds.), Textbook of Pulmonary Vascular Disease (CHAPTER 97).

    Case Report

    1. Ferrel MN, Ryan JJ, Han FT (2022). Acute myeloid leukemia causing acute thrombosis of the coronary arteries: a case report. J Med Case Rep, 16(1), 149. (Read full article)
    2. Ferrel MN, Iriana S, Raymond Thomason I, Ma CL, Tsarova K, Wilson BD, McKellar SH, Ryan JJ (2021). Constrictive pericarditis in the setting of repeated chest trauma in a mixed martial arts fighter. BMC Cardiovasc Disord, 21(1), 561. (Read full article)
    3. Pugh A, Tonna JE, Youngquist S, Ryan JJ, Brant-Zawadzki G (2020). Emergency department extracorporeal membrane oxygenation as a rescue therapy for ventricular tachycardia electrical storm: a case report. J Am Coll Emerg Physicians Open, 1(4), 371-374. (Read full article)
    4. Pan IZ, Carey JR, Jacobs JA, Dechand J, Sessions JJ, Sorensen T, Penn BA, Mayeux JD, Hatton ND, Ryan JJ (2020). Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension. Front Med (Lausanne), 7, 81. (Read full article)
    5. Kundu A, Sardar P, Sen P, Chatterjee S, Huston J, Nairooz R, Ryan JJ, Aronow WS (2015). Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding. J Atr Fibrillation, 8(3), 1218. (Read full article)
    6. Ryan JJ, Swamy RS, Shah AP (2011). Sudden cardiac death due to large coronary aneurysm successfully treated with a covered stent and ChromaFlo guidance. J Invasive Cardiol, 23(2), E22-5. (Read full article)
    7. Ryan AM, Ryan JJ, Wan-Ahmed M, Hardiman O, Farrell MA, McNamara B, Sweeney BJ (2007). Vacuolar leucoencephalopathy and pulvinar sign in association with coeliac disease. J Neurol Neurosurg Psychiatry, 78(1), 98-9.

    Editorial

    1. Gilbertson EA, Hatton ND, Ryan JJ (2020). Point of care ultrasound: the next evolution of medical education. Ann Transl Med, 8(14), 846. (Read full article)
    2. Ferrel MN, Ryan JJ (2020). The Impact of COVID-19 on Medical Education. Cureus, 12(3), e7492. (Read full article)
    3. Beck EM, Hatton ND, Ryan JJ (2019). Novel techniques for advancing our understanding of pulmonary arterial hypertension. Eur Respir J, 53(5). (Read full article)
    4. Catino AB, Ryan JJ (2019). A Change in Focus. Circ Cardiovasc Imaging, 12(5), e009186. (Read full article)
    5. Cirulis MM, Ryan JJ (2018). Who's Who of Pulmonary Hypertension: Redefining Classification to Advance Precision Care. Circ Genom Precis Med, 11(4), e002116. (Read full article)
    6. Mathai SC, Ryan JJ (2018). The Growing Burden of Pulmonary Hypertension in the Modern Era: A Zebra No More? Circ Cardiovasc Qual Outcomes, 11(2), e004536. (Read full article)
    7. Hatton N, Ryan JJ (2014). The complicated question of anticoagulation in pulmonary arterial hypertension: time to get some simple answers. Can J Cardiol, 30(8), 850-2. (Read full article)
    8. Hatton N, Ryan JJ (2014). Sex differences in response to pulmonary arterial hypertension therapy: is what's good for the goose, good for the gander? Chest, 145(6), 1184-1186. (Read full article)
    9. Luo N, Ryan JJ (2013). Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition. Can J Cardiol, 29(6), 659-61. (Read full article)
    10. Thenappan T, Ryan JJ, Archer SL (2012). Evolving Epidemiology of Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med, 186, 707-709.
    11. Ryan JJ, Rich S, Archer SL (2011). Pulmonary endarterectomy surgery--a technically demanding cure for WHO Group IV Pulmonary Hypertension: requirements for centres of excellence and availability in Canada. Can J Cardiol, 27(6), 671-4. (Read full article)
    12. Ryan JJ, Rehman J, Archer SL (2011). Paracrine proliferative signaling by senescent cells in world health organization group 3 pulmonary hypertension: age corrupting youth? Circ Res, 109(5), 476-9. (Read full article)

    Letter

    1. Lee JD, Burger CD, Rayner SG, Ryan JJ, Leary PJ (2021). Reply: COVID-19 Experience and Pulmonary Arterial Hypertension: Do Earlier Theses and New Data Still Match? [Letter to the editor]. Ann Am Thorac Soc, 18(6), 1081-1082. (Read full article)
    2. Jacobs JA, Ryan JJ (2020). Clinical uncertainty for the use of rivaroxaban in obesity. [Letter to the editor]. J Thromb Haemost, 19(3), 870-871. (Read full article)
    3. Bunsawat K, Ratchford SM, Alpenglow JK, Ryan JJ, Richardson RS, Wray DW (2020). Direct Assessment of Muscle Sympathetic Nerve Activity During Exercise in Heart Failure With Preserved Ejection Fraction: A Case Report. [Letter to the editor]. J Card Fail, 27(1), 114-116. (Read full article)
    4. Ryan JJ, Maron BA (2020). Vericiguat in Heart Failure with Reduced Ejection Fraction. [Letter to the editor]. N Engl J Med, 383(15), 1497. (Read full article)
    5. Klinger JR, Elliott G, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB (2019). Response. [Letter to the editor]. Chest, 156(1), 187-188. (Read full article)
    6. Cirulis MM, Liou TG, Ryan JJ (2018). RV/LV ratio in severe sepsis and septic shock: Response to Letter to the Editor. [Letter to the editor]. J Crit Care, 50, 311-312. (Read full article)
    7. Leary PJ, Hess E, Barn AE, Branch KR, Choudhary G, Hough CL, Maron BA, Ralph DD, Ryan JJ, Tedford RJ, Weiss NS, Zamanian RT, Lahm T (2018). H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program. [Letter to the editor]. Am J Respir Crit Care Med, 197(12), 1638-1641. (Read full article)
    8. Ryan JJ, Kalscheur M, Dellefave L, McNally E, Archer SL (2012). A KCNE1 missense variant (V47I) causing exercise-induced long QT syndrome (Romano Ward). [Letter to the editor]. Int J Cardiol, 156(2), e33-5. (Read full article)
    9. Ryan AM, Ryan J, Wan-Ahmed M, Hardiman O, Farrell MA, McNamara B, Sweeney BJ (2007). Vacuolar leucoencephalopathy and pulvinar sign in association with coeliac disease. [Letter to the editor]. J Neurol Neurosurg Psychiatry, 78(1), 98-9. (Read full article)

    Other

    1. Francisco MA, Lee JF, Barrett-OKeefe Z, Groot HJ, Ratchford SM, Bunsawat K, Alpenglow JK, Ryan JJ, Nativi JN, Richardson RS, Wray DW (2021). Locomotor Muscle Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Hypertension (78(6), pp. 1750-1759). United States. (Read full article)
    2. Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, Lamba S, Sharma K, Khan SS, Chandra L, Gordon RA, Ryan JJ, Chaudhry SP, Joseph SM, Chow CH, Kanwar MK, Pursley M, Siraj ES, Lewis GD, Clemson BS, Fong M, Kosiborod MN (2021). The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med (27(11), pp. 1954-1960). United States. (Read full article)
    3. Ryan JJ (2004). Author of several hundred columns for the 'weekly column' of Ireland's leading medical newspapers. Medicine Weekly and Irish Medical Times.

    Video/Film/CD/Web/Podcast

    1. Ryan JJ (2012). Digital Business Strategy [Web]. American College of Cardiology.
    2. Ryan JJ (2012). Usability Project, Fellows-In-Training representative. [Web]. CardioSource.

  • News & Podcasts

    News

    Podcasts